(VIANEWS) – EPR Properties (EPR), Merck (MRK), Hawaiian Electric Industries (HE) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up to now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. EPR Properties (EPR)
170.98% Payout Ratio
EPR Properties is a leading experiential net lease real estate investment trust (REIT), specializing in select enduring experiential properties in the real estate industry. We focus on real estate venues which create value by facilitating out of home leisure and recreation experiences where consumers choose to spend their discretionary time and money. We have nearly $6.7 billion in total investments across 44 states. We adhere to rigorous underwriting and investing criteria centered on key industry, property and tenant level cash flow standards. We believe our focused approach provides a competitive advantage and the potential for stable and attractive returns.
Earnings Per Share
As for profitability, EPR Properties has a trailing twelve months EPS of $1.93.
PE Ratio
EPR Properties has a trailing twelve months price to earnings ratio of 25.08. Meaning, the purchaser of the share is investing $25.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.74%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.2%, now sitting on 705.88M for the twelve trailing months.
2. Merck (MRK)
162.22% Payout Ratio
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates and a collaboration with HiberCell, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, Merck has a trailing twelve months EPS of $1.8.
PE Ratio
Merck has a trailing twelve months price to earnings ratio of 64.96. Meaning, the purchaser of the share is investing $64.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.77%.
Sales Growth
Merck’s sales growth is negative 5.2% for the current quarter and negative 2.1% for the next.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 13, 2023, the estimated forward annual dividend rate is 3.08 and the estimated forward annual dividend yield is 2.83%.
Volume
Today’s last reported volume for Merck is 2974810 which is 64.17% below its average volume of 8304070.
Previous days news about Merck (MRK)
- According to Zacks on Friday, 5 January, "In the last five trading sessions, all the stocks were in the green, with Merck rising the most (7.6%)."
- According to Zacks on Wednesday, 3 January, "Over the next two years, Oppenheimer analysts expect Moderna to secure three FDA approvals - mRNA-1345 (RSV vaccine), mRNA-1010 (influenza vaccine) and Merck (MRK Quick QuoteMRK – Free Report) -partnered mRNA-4157/V940 [individualized neoantigen therapy (INT) targeting oncology indications]."
- Why the market dipped but Merck (mrk) gained today. According to Zacks on Wednesday, 3 January, "The latest trading session saw Merck (MRK Quick QuoteMRK – Free Report) ending at $114.77, denoting a +1.35% adjustment from its last day’s close. ", "The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. "
- According to Zacks on Wednesday, 3 January, "In October 2023, Merck FDA’s approval for Keytruda for the treatment of patients with resectable NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. "
- According to Zacks on Wednesday, 3 January, "In December 2023, CCCC entered into an exclusive licensing and collaboration agreement with pharma giant Merck (MRK Quick QuoteMRK – Free Report) to discover and develop degrader-antibody conjugates ("DACs") with an initial focus on one oncology target.", "The proceeds of the deal with Merck are likely to provide C4T with the required funds to support its pipeline development and continue its research activities. "
3. Hawaiian Electric Industries (HE)
75.66% Payout Ratio
Hawaiian Electric Industries, Inc., together with its subsidiaries, engages in the electric utility, banking, and renewable/sustainable infrastructure investment businesses in the state of Hawaii. It operates in three segments: Electric Utility, Bank, and Other. The Electric Utility segment engages in the production, purchase, transmission, distribution, and sale of electricity in the islands of Oahu, Hawaii, Maui, Lanai, and Molokai. Its renewable energy sources and potential sources include wind, solar, photovoltaic, geothermal, wave, hydroelectric, municipal waste, and other biofuels. This segment serves suburban communities, resorts, the United States armed forces installations, and agricultural operations. The Bank segment operates a community bank that offers banking and other financial services to consumers and businesses, including savings and checking accounts; and loans comprising residential and commercial real estate, residential mortgage, construction and development, multifamily residential and commercial real estate, consumer, and commercial loans. This segment operates 42 branches, including 29 branches in Oahu, 6 branches in Maui, 4 branches in Hawaii, 2 branches in Kauai, and 1 branch in Molokai. The Other segment invests in non-regulated renewable energy and sustainable infrastructure in the State of Hawaii. Hawaiian Electric Industries Inc. was incorporated in 1891 and is headquartered in Honolulu, Hawaii.
Earnings Per Share
As for profitability, Hawaiian Electric Industries has a trailing twelve months EPS of $1.89.
PE Ratio
Hawaiian Electric Industries has a trailing twelve months price to earnings ratio of 7.31. Meaning, the purchaser of the share is investing $7.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.33%.
4. Amgen (AMGN)
59.25% Payout Ratio
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $14.07.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 21.34. Meaning, the purchaser of the share is investing $21.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 133.8%.
Yearly Top and Bottom Value
Amgen’s stock is valued at $300.25 at 07:23 EST, higher than its 52-week high of $289.04.
Volume
Today’s last reported volume for Amgen is 587433 which is 76.7% below its average volume of 2521350.
Sales Growth
Amgen’s sales growth is 7.5% for the present quarter and 11.9% for the next.
Previous days news about Amgen (AMGN)
- Why the market dipped but Amgen (amgn) gained today. According to Zacks on Thursday, 4 January, "In terms of valuation, Amgen is currently trading at a Forward P/E ratio of 15.17. "
5. BLACKROCK INTERNATIONAL, LTD. Blackrock International Real Estate Fund (BGY)
42.25% Payout Ratio
BlackRock Enhanced International Dividend Trust is a closed ended equity mutual fund launched by BlackRock, Inc. The fund is co-managed by BlackRock Advisors, LLC and BlackRock International Limited. It invests in public equity markets across the globe excluding the United States. The fund seeks to invest in stocks of companies operating across diversified sectors. It invests in stocks of companies across all market capitalizations. The fund also invests through the use of derivatives, with an emphasis on options writing. It benchmarks the performance of its portfolio against the S&P Global ex-U.S. Broad Market Index. The fund was formerly known as BlackRock International Growth and Income Trust. BlackRock Enhanced International Dividend Trust was formed on May 30, 2007 and is domiciled in the United States.
Earnings Per Share
As for profitability, BLACKROCK INTERNATIONAL, LTD. Blackrock International Real Estate Fund has a trailing twelve months EPS of $0.96.
PE Ratio
BLACKROCK INTERNATIONAL, LTD. Blackrock International Real Estate Fund has a trailing twelve months price to earnings ratio of 5.48. Meaning, the purchaser of the share is investing $5.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.23%.
Moving Average
BLACKROCK INTERNATIONAL, LTD. Blackrock International Real Estate Fund’s value is higher than its 50-day moving average of $5.08 and under its 200-day moving average of $5.26.
Volume
Today’s last reported volume for BLACKROCK INTERNATIONAL, LTD. Blackrock International Real Estate Fund is 242826 which is 4.3% below its average volume of 253743.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
1’s EBITDA is 1.
